| dc.creator |
Selek, Ugur |
|
| dc.creator |
ÖZKAN, Emine Elif |
|
| dc.creator |
Topkan, Erkan |
|
| dc.creator |
Pehlivan, Berrin |
|
| dc.creator |
Kucuk, Ahmet |
|
| dc.creator |
Ozturk, Duriye |
|
| dc.date |
2023-01-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:38:00Z |
|
| dc.date.available |
2025-02-25T10:38:00Z |
|
| dc.identifier |
c5f8bb85-8888-4699-aa4c-409d0097c78e |
|
| dc.identifier |
10.1177/03946320231187759 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/c5f8bb85-8888-4699-aa4c-409d0097c78e/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/101299 |
|
| dc.description |
Objectives: The objective of our study was to assess the prognostic significance of the Pan-Immune-Inflammation Value (PIV) before concurrent chemoradiation (C-CRT) and prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (SCLC). Methods: The medical records of LS-SCLC patients who underwent C-CRT and PCI between January 2010 and December 2021 were retrospectively analyzed. PIV values were calculated using the peripheral blood samples obtained within the past 7 days before the initiation of treatment: PIV = [neutrophils × platelets × monocytes] ÷ lymphocytes. Using receiver operating characteristic (ROC) curve analysis, the optimal pretreatment PIV cutoff values that can partition the study population into two groups with substantially distinct progression-free survival (PFS) and overall survival (OS) outcomes were determined. The relationship between PIV values and OS outcomes was the primary outcome measure. Results: Eighty-nine eligible patients were divided into two PIV groups at an optimal cutoff of 417 [Area under curve (AUC): 73.2%; sensitivity: 70.4%; specificity: 66.7%]: Group 1: PIV < 417 (N = 36) and Group 2: PIV ≥ 417 (N = 53). Comparative analyses revealed that patients with PIV < 417 had significantly longer OS (25.0 vs 14.0 months, p <.001) and PFS (18.0 vs 8.9 months, p =.004) compared to patients with PIV ≥ 417. The outcomes of the multivariate analysis have verified the independent significance of pretreatment PIV concerning PFS (p <.001) and OS (p <.001) outcomes. Conclusion: The findings of this retrospective study indicate that the pretreatment PIV is a reliable and independent prognostic biomarker for patients with LS-SCLC who were treated with C-CRT and PCI. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer |
|
| dc.type |
info:eu-repo/semantics/article |
|